| Document Date: 2014-11-10 10:17:25 Open Document File Size: 260,96 KBShare Result on Facebook
Country United States / / / Facility University Medical Center Freiburg Dept. / Freiburg University / University Hospital Freiburg / / / IndustryTerm therapy of minimal residual disease / prostate cancer therapy / immobilized metal affinity chromatography / Therapeutics for Prostate Cancer / / MedicalCondition frequent malignant disease / minimal residual disease Market Potential Prostate cancer / PSMA-negative tumors / tumor / human PSMA-expressing prostate cancer / Cancer / PSMA positive cancer / tumors / PSMA expressing prostate cancer / prostate cancers / PSMA expressing prostate carcinoma / insensitive and metastatic disease / PSMA expressing prostate cancers / prostate cancer SCID / PSMA expressing tumors / SCID / prostate cancer / metastases / prostate carcinoma / / MedicalTreatment immunotherapy / cancer therapy / adjuvant therapy / / Organization Freiburg University / U. Wetterauer Department of Urology / African Union / PE40 PBS / Freiburg University Medical Center / / Person Philipp Wolf / / / Position Innovation Responsible Scientist / / Technology antibodies / treating cancer / /
SocialTag |